Johnson & Johnson weekly recap: Q1—Q2 beats, raises guidance

The item recaps Johnson & Johnson’s Q1—Q2 results and a guidance raise, citing oncology and medtech momentum, pipeline wins (including PAPILLON), and a proposed $5.5B talc deal. It also notes proposed steady growth and dividends plus a Firefly buyout mention.